# US 2021/0260134 A1 · Compositions and Methods for Tissue Repair with Extracellular Matrices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260134 A1
- Document ID: US20210260134A1
- Status: Published application
- Kind: A1
- Application number: 17/135,785
- Filed: 2020-12-28
- Published: 2021-08-26
- Earliest claimed: 2008-09-30
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Karen Christman; Jennifer Singelyn; Jessica DeQuach
- Web page: https://patentgrep.com/patent/US20210260134A1

## CPC

- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/52: Hydrogels or hydrocolloids
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of producing a composition comprising decellularized cardiac extracellular matrix comprising:
(a) obtaining a cardiac tissue sample having an extracellular matrix component and non-extracellular matrix component;
(b) processing the cardiac tissue sample to remove the non-extracellular matrix component to obtain decellularized cardiac extracellular matrix; and
(c) sterilizing the decellularized cardiac extracellular matrix.

### Claim 22 (depends on 21)

The method of claim 21, wherein said method further comprises the step of lyophilizing and grinding up the decellularized cardiac extracellular matrix.

### Claim 23 (depends on 21)

The method of claim 21, wherein said method further comprises the step of enzymatically treating the decellularized cardiac extracellular.

### Claim 24 (depends on 21)

The method of claim 21, wherein said decellularized cardiac extracellular matrix is digested with pepsin at a pH below 7.

### Claim 25 (depends on 21)

The method of claim 21, wherein said method further comprises the step of suspending and neutralizing said decellularized cardiac extracellular matrix in a saline buffered solution.

### Claim 26 (depends on 25)

The method of claim 25, wherein said solution can be injected through a high gauge needle into the myocardium.

### Claim 27 (depends on 25)

The method of claim 25, wherein said solution spontaneously forms into a gel at body temperature.

### Claim 28 (depends on 25)

The method of claim 25, wherein said solution further comprises cells, or other therapeutic agents.

### Claim 29 (depends on 25)

The method of claim 25, wherein said solution is placed into tissue culture plates or wells, incubated at 37° C. to form into a gel.

### Claim 30 (depends on 21)

The method of claim 21, further comprising a step of adjusting at least one of pH, salt concentration, and temperature of the composition.

### Claim 31 (depends on 26)

The method of claim 26, wherein the needle of the catheter is 22 gauge or higher.

### Claim 32 (depends on 25)

The method of claim 25, wherein the decellularized extracellular matrix concentration in the solution is about 1 mg/ml to about 20 mg/ml.

### Claim 33 (depends on 32)

The method of claim 32, wherein the decellularized extracellular matrix concentration in the solution is about 2 mg/ml to about 8 mg/ml.

### Claim 34 (depends on 21)

The method of claim 21, further comprising processing the cardiac tissue sample with a detergent to remove the non-extracellular matrix component to obtain decellularized cardiac extracellular matrix.

### Claim 35 (depends on 34)

The method of claim 34, wherein the detergent comprises SDS.
